Related Experiment Videos
Experimental chemonucleolysis with chondroitinase ABC in monkeys
T Sugimura1, F Kato, K Mimatsu
1Department of Orthopaedic Surgery, Chubu Rosai Hospital, Nagoya-City, Japan.
Spine
|January 15, 1996
Summary
Chondroitinase ABC causes selective disc degradation with less toxicity than chymopapain in monkeys. This enzyme shows potential for clinical use in chemonucleolysis, with some recovery observed in treated discs.
Area of Science:
- Biochemistry
- Orthopedics
- Regenerative Medicine
Background:
- Chemonucleolysis research often uses rabbits, necessitating studies in more human-similar animals.
- Chondroitinase ABC is a key enzyme for disc degeneration research.
Purpose of the Study:
- To compare the effects of chondroitinase ABC and chymopapain on intervertebral discs in rhesus monkeys.
- To evaluate the clinical applicability of chondroitinase ABC.
Main Methods:
- Experimental chemonucleolysis using chondroitinase ABC and chymopapain in rhesus monkey lumbar intervertebral discs.
- Morphological and biochemical analysis of disc tissues post-injection.
- Short-term (6 weeks) and longer-term follow-up studies.
Main Results:
- Chymopapain caused more severe disc degeneration than chondroitinase ABC.
- Chondroitinase ABC led to a greater decrease in hyaluronic acid, chondroitin sulfate, and dermatan sulfate.
- Discs treated with chondroitinase ABC showed partial morphological and biochemical recovery over time.
Conclusions:
- Chondroitinase ABC achieves selective in vivo degradation of intervertebral discs.
- Chondroitinase ABC demonstrates lower disc toxicity compared to chymopapain.
- Chondroitinase ABC holds significant potential for clinical chemonucleolysis applications.